Diabetes, Vol 46, Issue 7 1182-1188, Copyright © 1997 by American Diabetes Association

ARTICLES

Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy

FS Nielsen, P Rossing, MA Gall, P Skott, UM Smidt and HH Parving
Steno Diabetes Center, Gentofte, Denmark.

The aim of our study was to evaluate whether inhibition of ACE (lisinopril 10-20 mg/day) can reduce the rate of decline in kidney function more than reducing blood pressure with conventional antihypertensive treatment (atenolol 50-100 mg/day), usually in combination with a diuretic. We performed a prospective, randomized, parallel study for 42 months, double blind for the first 12 months and single blind thereafter. Forty-three (21 lisinopril and 22 atenolol) hypertensive NIDDM patients with diabetic nephropathy were enrolled. Data from 36 patients (17 lisinopril and 19 atenolol, 60 +/- 7 years of age, 27 men) who completed at least 12 months of the study period are presented. At baseline, the two groups were comparable: glomerular filtration rate (51Cr-EDTA plasma clearance) was 75 +/- 6 and 74 +/- 8 ml x min(-1) x 1.73 m(-2), mean 24-h ambulatory blood pressure (A&D TM2420) was 110 +/- 3 and 114 +/- 2 mmHg, and 24-h urinary albumin excretion rate was 961 (range 331-5,727) and 1,578 (476-5,806) mg/24 h in the lisinopril and atenolol groups, respectively. The mean follow-up time was similar, 37 and 35 months in the lisinopril and atenolol groups, respectively. Mean ambulatory blood pressure was equally reduced in the two groups, 12 +/- 2 and 10 +/- 2 mmHg in the lisinopril and atenolol groups, respectively. Glomerular filtration rate declined in a biphasic manner with a faster initial (0 to 6 months) change of 1.25 +/- 0.49 and 0.81 +/- 0.29 ml x min(-1) x month(-1) followed by a slower sustained decline (6 to 42 months) of 0.59 +/- 0.10 and 0.54 +/- 0.13 ml x min(-1) x month(-1) in the lisinopril and atenolol groups, respectively. No significant differences were observed in either initial or sustained decline in glomerular filtration rate between the two groups. Urinary albumin excretion was reduced (% reduction of baseline) more in the lisinopril than in the atenolol group, at 55 (95% CI 29-72) and 15% (-13 to 34), respectively (P = 0.01). In conclusion, the relentless decline in kidney function characteristically found in hypertensive NIDDM patients with diabetic nephropathy can be reduced equally effectively by two antihypertensive treatments, the beta-blocker atenolol and the ACE inhibitor lisinopril.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Rahman, S. Pressel, B. R. Davis, C. Nwachuku, J. T. Wright Jr, P. K. Whelton, J. Barzilay, V. Batuman, J. H. Eckfeldt, M. Farber, et al. Renal Outcomes in High-Risk Hypertensive Patients Treated With an Angiotensin-Converting Enzyme Inhibitor or a Calcium Channel Blocker vs a Diuretic: A Report From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med, April 25, 2005; 165(8): 936 - 946. [Abstract] [Full Text] [PDF]

				M. Ravera, E. Ratto, S. Vettoretti, D. Parodi, and G. Deferrari Prevention and Treatment of Diabetic Nephropathy: The Program for Irbesartan Mortality and Morbidity Evaluation J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S48 - S52. [Abstract] [Full Text] [PDF]

				N. Joss, C. Ferguson, C. Brown, C.J. Deighan, K.R. Paterson, and J.M. Boulton-Jones Intensified treatment of patients with type 2 diabetes mellitus and overt nephropathy QJM, April 1, 2004; 97(4): 219 - 227. [Abstract] [Full Text] [PDF]

				S. Vijan and R. A. Hayward Blood Pressure Control in Type 2 Diabetes Mellitus Ann Intern Med, March 16, 2004; 140(6): 487 - 488. [Full Text] [PDF]

				G. Deferrari, M. Ravera, V. Berruti, G. Leoncini, and L. Deferrari Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S6 - 11. [Abstract] [Full Text]

				T. Berl Angiotensin-Converting Enzyme Inhibitors versus AT1 Receptor Antagonist in Cardiovascular and Renal Protection: The case for AT1 Receptor Antagonist J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S71 - 76. [Abstract] [Full Text]

				A. V. Crowe, M. Howse, S. Vinjamuri, G. J. Kemp, and P. S. Williams The antiproteinuric effect of losartan is systemic blood pressure dependent Nephrol. Dial. Transplant., October 1, 2003; 18(10): 2160 - 2164. [Abstract] [Full Text] [PDF]

				K. Rossing, P. Jacobsen, L. Pietraszek, and H.-H. Parving Renoprotective Effects of Adding Angiotensin II Receptor Blocker to Maximal Recommended Doses of ACE Inhibitor in Diabetic Nephropathy: A randomized double-blind crossover trial Diabetes Care, August 1, 2003; 26(8): 2268 - 2274. [Abstract] [Full Text] [PDF]

				S. Vijan and R. A. Hayward Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care Ann Intern Med, April 1, 2003; 138(7): 593 - 602. [Abstract] [Full Text] [PDF]

				K. Rossing, P. K. Christensen, B. V. Hansen, B. Carstensen, and H.-H. Parving Optimal Dose of Candesartan for Renoprotection in Type 2 Diabetic Patients With Nephropathy: A double-blind randomized cross-over study Diabetes Care, January 1, 2003; 26(1): 150 - 155. [Abstract] [Full Text] [PDF]

				L. Vogt, G. Navis, and D. de Zeeuw Renoprotection: A Matter of Blood Pressure Reduction or Agent-Characteristics? J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S202 - 207. [Abstract] [Full Text] [PDF]

				G. Deferrari, M. Ravera, L. Deferrari, S. Vettoretti, E. Ratto, and D. Parodi Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus: Angiotensin II Receptor Blockers J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S224 - 229. [Abstract] [Full Text]

				G. Remuzzi, A. Schieppati, and P. Ruggenenti Nephropathy in Patients with Type 2 Diabetes N. Engl. J. Med., April 11, 2002; 346(15): 1145 - 1151. [Full Text] [PDF]

				N. Joss, K.R. Paterson, C.J. Deighan, K. Simpson, and J.M. Boulton-Jones Diabetic nephropathy: how effective is treatment in clinical practice? QJM, January 1, 2002; 95(1): 41 - 49. [Abstract] [Full Text] [PDF]

				K. Rossing, P. K. Christensen, B. R. Jensen, and H.-H. Parving Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy: A randomized double-blind crossover study Diabetes Care, January 1, 2002; 25(1): 95 - 100. [Abstract] [Full Text] [PDF]

				C. Arauz-Pacheco, M. A. Parrott, and P. Raskin The Treatment of Hypertension in Adult Patients With Diabetes Diabetes Care, January 1, 2002; 25(1): 134 - 147. [Full Text] [PDF]

				B. M. Brenner, M. E. Cooper, D. de Zeeuw, W. F. Keane, W. E. Mitch, H.-H. Parving, G. Remuzzi, S. M. Snapinn, Z. Zhang, S. Shahinfar, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy N. Engl. J. Med., September 20, 2001; 345(12): 861 - 869. [Abstract] [Full Text] [PDF]

				T. Aizawa, N. Ishizaka, J.-i. Taguchi, R. Nagai, I. Mori, S.-S. Tang, J. R. Ingelfinger, and M. Ohno Heme Oxygenase-1 Is Upregulated in the Kidney of Angiotensin II-Induced Hypertensive Rats : Possible Role in Renoprotection Hypertension, March 1, 2000; 35(3): 800 - 806. [Abstract] [Full Text] [PDF]

				E. Ritz and S. R. Orth Nephropathy in Patients with Type 2 Diabetes Mellitus N. Engl. J. Med., October 7, 1999; 341(15): 1127 - 1133. [Full Text] [PDF]